Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
Top Cited Papers
- 21 November 2019
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 381 (21), 1995-2008
- https://doi.org/10.1056/nejmoa1911303
Abstract
In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.Keywords
Funding Information
- AstraZeneca plc
This publication has 21 references indexed in Scilit:
- Sodium Glucose Cotransporter-2 Inhibition in Heart FailureCirculation, 2017
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart FailureJAMA Cardiology, 2017
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesThe New England Journal of Medicine, 2017
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesThe New England Journal of Medicine, 2016
- A win ratio approach to comparing continuous non‐normal outcomes in clinical trialsPharmaceutical Statistics, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesThe New England Journal of Medicine, 2015
- Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chancesEuropean Journal of Heart Failure, 2015
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureThe New England Journal of Medicine, 2014
- Semiparametric Regression for the Mean and Rate Functions of Recurrent EventsJournal of the Royal Statistical Society Series B: Statistical Methodology, 2000
- Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failureJournal of the American College of Cardiology, 2000